141 related articles for article (PubMed ID: 34847284)
1. RAS mutation and associated risk of malignancy in the thyroid gland: An FNA study with cytology-histology correlation.
Gilani SM; Abi-Raad R; Garritano J; Cai G; Prasad ML; Adeniran AJ
Cancer Cytopathol; 2022 Apr; 130(4):284-293. PubMed ID: 34847284
[TBL] [Abstract][Full Text] [Related]
2. The histologic outcomes of indeterminate thyroid nodules with rat sarcoma mutations: A case series.
Jones M; Abendano DG; Turner M; Sullivan C; Reyes MCD
Diagn Cytopathol; 2023 Dec; 51(12):E332-E337. PubMed ID: 37583345
[TBL] [Abstract][Full Text] [Related]
3. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
4. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
[TBL] [Abstract][Full Text] [Related]
5. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
[TBL] [Abstract][Full Text] [Related]
6. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
[TBL] [Abstract][Full Text] [Related]
7. Utilities of
Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
[No Abstract] [Full Text] [Related]
8. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations.
Paulson VA; Shivdasani P; Angell TE; Cibas ES; Krane JF; Lindeman NI; Alexander EK; Barletta JA
Thyroid; 2017 Apr; 27(4):506-511. PubMed ID: 28114855
[TBL] [Abstract][Full Text] [Related]
9. Combination of ultrasound and molecular testing in malignancy risk estimate of Bethesda category IV thyroid nodules: results from a single-institution prospective study.
Marina M; Zatelli MC; Goldoni M; Del Rio P; Corcione L; Martorana D; Percesepe A; Bonatti F; Mozzoni P; Crociara A; Ceresini G
J Endocrinol Invest; 2021 Dec; 44(12):2635-2643. PubMed ID: 33860907
[TBL] [Abstract][Full Text] [Related]
10. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
11. Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypia.
Gajzer DC; Tjendra Y; Kerr DA; Algashaamy K; Zuo Y; Menendez SG; Jorda M; Garcia-Buitrago M; Gomez-Fernandez C; Velez Torres JM
Cancer Cytopathol; 2022 Nov; 130(11):881-890. PubMed ID: 35775861
[TBL] [Abstract][Full Text] [Related]
12. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules.
Eszlinger M; Krogdahl A; Münz S; Rehfeld C; Precht Jensen EM; Ferraz C; Bösenberg E; Drieschner N; Scholz M; Hegedüs L; Paschke R
Thyroid; 2014 Feb; 24(2):305-13. PubMed ID: 23837487
[TBL] [Abstract][Full Text] [Related]
13. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
14. EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology and co-mutation profiles.
Elsherbini N; Kim DH; Payne RJ; Hudson T; Forest VI; Hier MP; Payne AE; Pusztaszeri MP
J Otolaryngol Head Neck Surg; 2022 Nov; 51(1):43. PubMed ID: 36371345
[TBL] [Abstract][Full Text] [Related]
15. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy.
Decaussin-Petrucci M; Descotes F; Depaepe L; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Lopez J
Cytopathology; 2017 Dec; 28(6):482-487. PubMed ID: 29094776
[TBL] [Abstract][Full Text] [Related]
16. Does a higher American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) score forecast an increased risk of malignancy? A correlation study of ACR TI-RADS with FNA cytology in the evaluation of thyroid nodules.
Modi L; Sun W; Shafizadeh N; Negron R; Yee-Chang M; Zhou F; Simsir A; Sheth S; Brandler TC
Cancer Cytopathol; 2020 Jul; 128(7):470-481. PubMed ID: 32078249
[TBL] [Abstract][Full Text] [Related]
17. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy.
Moses W; Weng J; Sansano I; Peng M; Khanafshar E; Ljung BM; Duh QY; Clark OH; Kebebew E
World J Surg; 2010 Nov; 34(11):2589-94. PubMed ID: 20703476
[TBL] [Abstract][Full Text] [Related]
18. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
Macerola E; Rago T; Proietti A; Basolo F; Vitti P
J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
[TBL] [Abstract][Full Text] [Related]
19. Detection of RAS mutation by pyrosequencing in thyroid cytology samples.
Guerra A; Carrano M; Angrisani E; Puzziello A; Izzo G; Di Crescenzo V; Vatrella A; Vitale M
Int J Surg; 2014; 12 Suppl 1():S91-4. PubMed ID: 24866065
[TBL] [Abstract][Full Text] [Related]
20. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
